Cardiovascular risks of selective COX-2-inhibitors;Kardiovaskuläre risiken von COX-2-hemmern

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 49, 2004, Pages 2653-2656

  Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LUMIRACOXIB; PARECOXIB; ROFECOXIB; VALDECOXIB;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG PROTEIN BINDING; HEMOSTASIS; HUMAN; PROTEIN EXPRESSION;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 10644289540     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-836091     Document Type: Article

References (13)

1. Alsalameh S, Burian M, Mahr G, Woodcock BG, Geisslinger G. Review article: the pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2003; 17: 489-501
2. Bombardier C, Laine L, Reicin A et al for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528
3. Farkouh ME, Korshner H, Harrington RA et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 675-684
4. FDA CLASS Advisory Committee. CLASS Advisory Committee briefing document. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefmg/3677bl_01_searle. pdf, 2001
5. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Drug Disc 2003; 2: 879-890
6. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351: 1709-1711
7. John S, Schmieder R E. Beeinflussen COX-2-Inhibitoren das kardiovaskuläre Risiko? Dtsch Med Wochenschr 2002; 127: 156-159
8. Jüni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs? Br Med J 2002; 324: 1287-1288
9. Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 4999-5007
10. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002; 63: 817-821
11. Schnitzer TJ, Burmester GR, Mysler E et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364: 665-674
12. Schwabe U, Paffrath D (Hrsg). Arzneiverordnungsreport 2004, Springer Verlag Berlin-Heidelberg-New York, ISBN 3-540-21359-7
13. Zimmermann KC, Sarbia M, Schrör K, Weber A-A. Constitutive cyclooxygenase-2-expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998; 54: 536-540